Information Related to Clinical Trials
TaiRx’s novel anti-cancer drug CVM-1118 is currently in Phase II clinical program.
If you would like to learn more information regarding the clinical trials, please contact the nearest clinical trial center.
News
Company Announcement for Zelnite®
2024/7/17 TaiRx, Inc. hereby declares that Zelnite® is the only selenium injection product [...]
TaiRx‘s injectable product, Zelnite®, has been approved by TFDA to add high dosage and change drug labeling
2024/5/9 In 2018, TaiRx received approval from the Food and Drug Administration (TFDA) [...]
TaiRx’s sodium selenite pentahydrate—SelenOne®—earned the Symbol of National Quality (SNQ) in 2022 for its affirmed safety and quality for use as a food additive.
2022/12/23 In December 2022, TaiRx’s proprietary sodium selenite pentahydrate, [...]